Our Blog

Novartis Takes First Steps Into Performance-based Pricing


Novartis has entered a performance-based pricing pact with U.S. health insurance majors Cigna and Aetna for Entresto, its new congestive heart failure drug.

The novel deal crafts payment schemes based on patient outcomes and comes as drug companies are under pressure to lower prices. Cigna says the deal ties the price of Entresto to how well it improves the health of patients relative to its performance in clinical trials. @ Drug Discovery & Development

Comments ( 0 )

    Leave A Comment

    Your email address will not be published. Required fields are marked *